MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer

Lee, James Cheng Yen; Gundara, Justin S.; Glover, Anthony; Serpell, Jonathan W.; Sidhu, Stan

doi:10.1634/theoncologist.2014-0135

Cited by 40 publications

(37 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miRNAs serve important roles in the formation and progression of PTC by regulating numerous physiological and pathological behaviours (24,25). Hence, investigating the functional roles of specific miRNAs in PTC may contribute in identifying effective therapeutic targets for the management of patients with PTC.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

Liu

Guo²,

Chai

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

MicroRNAs (miRs) serve important roles in the formation and progression of papillary thyroid cancer (PTC) by regulating numerous physiological and pathological behaviours. Thus, investigating the functional roles of specific miRNAs in PTC may contribute in identifying effective therapeutic targets for the management of patients with PTC. miR-744 is emerging as a cancer-associated miRNA in numerous types of human cancers; however, the expression and specific functions of miR-744 in PTC are yet to be determined, and the mechanism underlying the regulatory roles of miR-744 in PTC remains unknown. In the present study, miR-744 expression was significantly decreased in PTC tissues and cell lines, as detected by reverse transcription-quantitative polymerase chain reaction. miR-744 restoration inhibited cell proliferation and invasion in PTC. Bioinformatics analysis predicted NIN1 (RPN12) binding protein 1 homolog (NOB1) as a potential target of miR-744. Subsequent experiments validated NOB1 as a direct target gene of miR-744 in PTC. Furthermore, NOB1 was upregulated in PTC tissues and negatively correlated with miR-744 expression. NOB1 overexpression could counteract miR-744-mediated antitumor effects on PTC cells. In summary, these findings indicated that miR-744 may inhibit the progression of PTC by directly targeting NOB1. The identification of the miR-744/NOB1 axis may provide insight into potential targets for the treatment of patients with PTC and improve their prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

Liu

Guo²,

Chai

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…9 It is reported that miRNAs were involved in every stage of PTC, including tumor diagnosis, prognosis, treatment and surveillance. 10 According to the small RNA deep-sequencing data, miR-873-5p expression in PTC is downregulated in tumors compared to normal samples. 11 However, the roles of miR-873-5p in PTC and the underlying molecular mechanisms remain unknown.…”

Section: Introductionmentioning

confidence: 99%

<p>miR-873-5p Inhibits Cell Migration and Invasion of Papillary Thyroid Cancer via Regulation of CXCL16</p>

Wang¹,

Liu²,

Wang³

et al. 2020

OTT

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) is the most common type of thyroid cancer with an increasing morbidity. MicroRNAs (miRNAs) play the pivotal roles in PTC occurrence and development. The aim of this study was to investigate the biological functions of miR-873-5p and its underlying molecular mechanisms in PTC. Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to detect miR-873-5p expressions in PTC tissues and cell lines. The target gene of miR-873-5p was predicted by TargetScan and confirmed by dual-luciferase reporter assay. Furthermore, cell proliferation, migration and invasion were assessed by CCK-8, wound healing assay and transwell assay, respectively. Additionally, the expressions of CXCL16, MMP1, MMP9 and MMP13 were measured by RT-qPCR and Western blot methods, and p65, Rel-B and their phosphorylation levels were examined by Western blot. Results: We found that miR-873-5p expression was downregulated in PTC tissues and cell lines. Moreover, CXCL16 was identified as a target of miR-873-5p, and its expression was upregulated in PTC tissues and cells at both mRNA and protein levels. Functionally, overexpression of miR-873-5p inhibited PTC cell proliferation, migration and invasion, while cotransfection of CXCL16 overexpression plasmid reversed the anti-tumor behaviors induced by miR-873-5p. In addition, miR-873-5p overexpression suppressed the phosphorylation of p65 and Rel-B, and decreased the mRNA and protein expression of MMP1, MMP9 and MMP13, while overexpression of CXCL16 partially abrogated the effects of miR-873-5p. Conclusion: MiR-873-5p functions as a tumor suppressor in PTC by inhibiting the proliferation, migration and invasion of the PTC cells via targeting CXCL16. These findings might provide a potential novel target for the therapy of PTC.

show abstract

“…Previous studies have reported that miRNAs are aberrantly expressed in almost all types of human cancer, including PTC (12), colorectal cancer (13), lung cancer (14), glioblastoma (15) MicroRNA-766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway and bladder cancer (16). Increasing evidence has revealed that various miRNAs are differentially expressed in PTC, and their dysregulation has been implicated in the regulation of PTC occurrence and development (17)(18)(19). Furthermore, miRNAs may have tumor suppressive or oncogenic roles in the progression of PTC and are able to regulate various cancer-associated biological processes, including cell proliferation, cell cycle progression, apoptosis, invasion, metastasis and epithelial-mesenchymal transition (20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway

Zhao

Chen

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs) are widely dysregulated in papillary thyroid cancer (PTC). Dysregulated miRNAs, together with their target genes, comprise a complex network that has been implicated in the regulation of PTC pathogenesis. Further knowledge of the functional roles of aberrantly expressed miRNAs in PTC, and the underlying molecular mechanisms, may assist in the identification of novel therapeutic targets. miR-766 has been well studied in human cancer; however, the expression status, specific roles and regulatory mechanisms of miR-766 in PTC remain unclear. The present study aimed to detect miR-766 expression in PTC tissues and cell lines, to explore the biological roles of miR-766 in the malignant biological behaviors of PTC cells, and to determine the underlying mechanism of action of miR-766 in PTC cells. The results revealed that miR-766 was downregulated in PTC tissues and cell lines, and its downregulation was strongly associated with TNM stage and lymph node metastasis. Overexpression of miR-766 inhibited PTC cell proliferation, colony formation, migration and invasion, promoted cell apoptosis and reduced tumor growth in vivo. Mechanistically, insulin receptor substrate 2 (IRS2) was identified as a direct target of miR-766 in PTC cells. IRS2 was upregulated in PTC tissues, and this was inversely correlated with miR-766 expression. Inhibition of IRS2 simulated the tumor suppressor activity of miR-766 in PTC cells. Restoration of IRS2 expression negated the tumor-suppressing effects of miR-766 overexpression on PTC cells. Notably, miR-766 directly targeted IRS2 to inhibit activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in PTC cells in vitro and in vivo. Overall, these findings indicated that miR-766 may inhibit the malignant biological behaviors of PTC cells by directly targeting IRS2 and regulating the PI3K/Akt pathway, thus suggesting that this miRNA may be a promising therapeutic target for PTC.

show abstract

MicroRNA Expression Profiles in the Management of Papillary Thyroid Cancer

Cited by 40 publications

References 54 publications

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1

<p>miR-873-5p Inhibits Cell Migration and Invasion of Papillary Thyroid Cancer via Regulation of CXCL16</p>

MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway

Contact Info

Product

Resources

About